Markus Y Mapara MD PhD

PubMed

• Long-term follow-up of patients with AL amyloidosis treated on a phase 1 trial of CAEL-101.
  Michael Sang Hughes, Samuel Pan, Rajshekhar Chakraborty, Jayant Raikhelkar, Mathew S Maurer
  Blood Advances. 2025-10-14
• Improvements in Health-Related Quality of Life in Patients with Transfusion-Dependent β-Thalassemia After Exagamglogene Autotemcel.
  Josu de la Fuente, Haydar Frangoul, Peter Lang, Donna Wall, Roland Meisel
  Blood Advances. 2025-08-19
• Improvements in Health-Related Quality of Life in Patients with Severe Sickle Cell Disease After Exagamglogene Autotemcel.
  Akshay Sharma, Franco Locatelli, Monica Bhatia, Lyndsay Molinari, Markus Y Mapara
  Blood Advances. 2025-08-19

Journal Articles

• Immunomodulatory Drugs Downregulate IKZF1 Leading to Expansion of Hematopoietic Progenitors with Concomitant Block of Megakaryocytic Maturation  
  Markus Y Mapara, Sara A Monaghan, Suzanne Lentzsch, Haematologica
• Brentuximab Vedotin and Bendamustine Produce High Complete Response Rates in Patients with Chemotherapy Refractory Hodgkin Lymphoma  
  Changchun Deng, Markus Y. Mapara, Ahmed Sawas, Matko Kalac, British Journal of Haematology

Abstracts/Posters

• Combination Chemotherapy with Carfilzomib, Bendamustine and Dexamethasone Is Highly Active for Therapy of Newly Diagnosed Multiple Myeloma-Results of Single Center Pha...
  Markus Y. Mapara, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Excellent Survival and Immune Reconstitution Following Matched/Mismatched Unrelated and Mismatched Related Transplantation in Adult Patients with Sickle Cell Disease: ...
  Markus Y Mapara, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Exploring the Drivers of Potential Clinical Benefit in Initial Patients Treated in the Hgb-206 Study of Lentiglobin for Sickle Cell Disease (SCD) Gene Therapy
  Markus Y. Mapara, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Resolution of Sickle Cell Disease Manifestations in Patients Treated with Lentiglobin Gene Therapy: Updated Results from the Phase 1/2 Hgb-206 Group C Study
  Markus Y. Mapara, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Autologous Transplant Recipients Have a Healthier Gut Microbiota at Baseline and Faster Recovery from Microbiome Injury Compared to Allogeneic Transplant Recipients
  Markus Y. Mapara, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Checkpoint Inhibitor PD-1H/VISTA Functions As MMP-13 Receptor on Osteoclasts and Mediates MMP-13 Induced Osteoclast Activation in Multiple Myeloma
  Markus Y. Mapara, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Gck Kinase Activity Is Critical for RAS Mutated Myeloma - a Potential Treatment Approach for Targeting Specific Mutations
  Markus Y Mapara, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Join now to see all

Lectures

• Outcomes for Initial Patient Cohorts with up to 33 Months of Follow-up in the Hgb-206 Phase 1 Trial 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018